The stock of Epizyme Inc (NASDAQ:EPZM) is a huge mover today! The stock increased 3.58% or $0.34 during the last trading session, hitting $9.84. About 441,587 shares traded hands. Epizyme Inc (NASDAQ:EPZM) has risen 3.15% since February 26, 2016 and is uptrending. It has underperformed by 7.28% the S&P500.
The move comes after 7 months positive chart setup for the $548.36M company. It was reported on Oct, 1 by Barchart.com. We have $15.35 PT which if reached, will make NASDAQ:EPZM worth $307.08 million more.
Analysts await Epizyme Inc (NASDAQ:EPZM) to report earnings on November, 14. They expect $-0.56 EPS, 0.00% or $0.00 from last year’s $-0.56 per share. After $-0.49 actual EPS reported by Epizyme Inc for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.
Epizyme Inc (NASDAQ:EPZM) Ratings Coverage
Out of 7 analysts covering Epizyme (NASDAQ:EPZM), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Epizyme has been the topic of 9 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Citigroup initiated the shares of EPZM in a report on Tuesday, April 5 with “Buy” rating. As per Thursday, August 6, the company rating was maintained by Mizuho. H.C. Wainwright upgraded Epizyme Inc (NASDAQ:EPZM) on Monday, March 14 to “Buy” rating. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. RBC Capital Markets maintained the shares of EPZM in a report on Monday, September 28 with “Outperform” rating. Mizuho maintained Epizyme Inc (NASDAQ:EPZM) rating on Tuesday, May 10. Mizuho has “Buy” rating and $18 price target. The rating was downgraded by Zacks to “Buy” on Tuesday, August 25.
According to Zacks Investment Research, “Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.64 in Q2 2016. Its down 1.17, from 2.81 in 2016Q1. The ratio fall, as 8 funds sold all Epizyme Inc shares owned while 20 reduced positions. 14 funds bought stakes while 32 increased positions. They now own 45.74 million shares or 3.00% more from 44.40 million shares in 2016Q1.
Jpmorgan Chase, a New York-based fund reported 224,156 shares. Proshare Advsrs Ltd Limited Liability Company accumulated 47,522 shares or 0.01% of the stock. Macquarie Grp Limited holds 0% or 20,000 shares in its portfolio. Fmr Lc last reported 0.01% of its portfolio in the stock. Swiss Savings Bank last reported 0% of its portfolio in the stock. Alliancebernstein Lp, a New York-based fund reported 40,600 shares. Jacobs Levy Equity Management reported 38,200 shares or 0.01% of all its holdings. Loring Wolcott & Coolidge Fiduciary Advsrs Llp Ma holds 3,000 shares or 0% of its portfolio. Principal Financial Group Inc Inc has 81,178 shares for 0% of their US portfolio. Tocqueville Asset Mgmt Ltd Partnership has invested 0% of its portfolio in Epizyme Inc (NASDAQ:EPZM). Trexquant Invest L P has invested 0.05% of its portfolio in Epizyme Inc (NASDAQ:EPZM). Tfs Cap Ltd Liability Corp has 0.26% invested in the company for 139,448 shares. Rock Springs Cap Mgmt Lp holds 597,500 shares or 0.45% of its portfolio. Jennison Llc last reported 0.02% of its portfolio in the stock. Cim Investment Mangement has 0.05% invested in the company for 11,055 shares.
Insider Transactions: Since April 11, 2016, the stock had 0 insider purchases, and 9 insider sales for $156,667 net activity. Singer Andrew E. sold 1,013 shares worth $9,166. Copeland Robert A sold $41,492 worth of stock or 4,000 shares.
More recent Epizyme Inc (NASDAQ:EPZM) news were published by: Globenewswire.com which released: “Epizyme Appoints Pamela Strode as Vice President, Regulatory Affairs and …” on September 29, 2016. Also Fool.com published the news titled: “Why Epizyme Inc, Akebia Therapeutics Inc, and Cempra Inc Got Wacked Today” on January 07, 2016. Twst.com‘s news article titled: “Epizyme Inc.: Epizyme Establishes Collaboration with Foundation Medicine to …” with publication date: September 21, 2016 was also an interesting one.
EPZM Company Profile
Epizyme, Inc., incorporated on November 1, 2007, is a clinical-stage biopharmaceutical company. The Firm discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. The Firm develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. The Firm develops small molecule inhibitors of other chromatin modifying proteins, or CMPs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.